J&J

PM Group Delivers Strong Operational and Financial Performance and Announces Creation of 400 New Jobs

Retrieved on: 
Thursday, September 9, 2021

This performance was achieved on the back of strong underlying fee income which was 9% up on prior year.

Key Points: 
  • This performance was achieved on the back of strong underlying fee income which was 9% up on prior year.
  • The Group is employee owned with over 1,000 people holding shares in the Group, up 15% on prior year.
  • PM Group is creating 400 new jobs this year across a range of disciplines including architecture, engineering, construction, data analytics, project controls and Environmental.
  • In April, the Group appointed a new Chief Financial Officer, Rosita Fennell in succession to Larry Westman.

NRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Wednesday, September 8, 2021

RADNOR, Pa., Sept. 8, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) today announced that NRx's management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference September 13-15, 2021.

Key Points: 
  • RADNOR, Pa., Sept. 8, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) today announced that NRx's management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference September 13-15, 2021.
  • Available on demand beginning September 13, 2021 at 7 AM EST
    NRx Pharmaceuticals (NRx) ( www.nrxpharma.com ) draws upon more than 300 years of collective, scientific and drug-development experience to bring improved health to patients.
  • NRx also has the BriLife vaccine for COVID-19 in clinical trials and holds the exclusive worldwide license to commercialize the vaccine.
  • NRx is led by executives who have held senior roles at Allergan, J&J, Lilly, Novartis, Pfizer, and the US FDA.

Outcry Continues to Grow for Johnson & Johnson to Resolve Talc-Cancer Claims After Latest Jury Verdict

Retrieved on: 
Tuesday, August 31, 2021
Judgement, Ovarian cancer, Johnson & Johnson, Cancer, Missouri Court of Appeals, Talc, Association, Appeal, Food, Regulation of tobacco by the U.S. Food and Drug Administration, JNJ, J&J, NYSE, Failure, Johnson's Baby, News, Asbestos, Supreme court, Woman, Supreme, Dietary supplement

Jurors in Alameda County awarded $26.5 million in compensatory damages against J&J for causing the mesothelioma cancer of 35-year-old Christina Prudencio, a former teacher.

Key Points: 
  • Jurors in Alameda County awarded $26.5 million in compensatory damages against J&J for causing the mesothelioma cancer of 35-year-old Christina Prudencio, a former teacher.
  • According to trial testimony of her mother and sister, Ms. Prudencio was directly and indirectly exposed to Johnson's Baby Powder for more than two decades.
  • In response to ongoing litigation and mounting jury verdicts, the company has threatened to bundle those liabilities into a separate entity, which would then seek bankruptcy protection.
  • Such a scheme would eliminate the rights of thousands of ovarian cancer victims to have their claims resolved before a judge and jury.

NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies

Retrieved on: 
Thursday, August 26, 2021
Cell death, VIP, ACE2, Blood, Fast Track, Human services, Food, Health, Hospital, Senior, Proning, Partnership, Aviptadil, Lung, Emergency Use Authorization, Medicine, ASPE, Biomedical Advanced Research and Development Authority, Cardinal Health, Vasoactive intestinal peptide, Lilly, MPH, US Foods, Enteroendocrine cell, General officer, Dark Enlightenment, Israel Institute for Biological Research, Coronavirus diseases, Letter, Critical, Nasdaq, EUA, IIBR-100, Biotechnology, Cardinal, Development, Goal, High-dependency unit, Novartis, FDA, United States Army, National, ATII, Strategic sourcing, Private Securities Litigation Reform Act, JD, J&J, Biology, Inflammation, Breathe Me, Patient, COVID-19, Breakthrough therapy, Pharmaceutical industry, Vaccine

This partnership creates an efficient and highly flexible logistics and distribution model for NRx.

Key Points: 
  • This partnership creates an efficient and highly flexible logistics and distribution model for NRx.
  • "This partnership creates an efficient and highly flexible logistics and distribution model for NRx.
  • Cardinal Health Specialty Pharmaceutical Distribution will serve as the exclusive distributor for ZYESAMI, providing broad access to hospitals for this needed medicine upon FDA authorization.
  • "Cardinal Health is pleased to ensure that COVID-19 patients get access to treatment in a timely and efficient manner."

Ovarian Cancer Victims Ask Court to Block Johnson & Johnson's 'Texas Two-Step' Bankruptcy Plan

Retrieved on: 
Tuesday, August 24, 2021
Judgement, Ovarian cancer, Black, Johnson & Johnson, Reuters, Missouri Court of Appeals, Talc, Association, Appeal, Research, Georgia-Pacific, Birchfield, Bankruptcy, JNJ, J&J, Cancer, Partnership, Inflammation, NYSE, File, Asbestos, Supreme court, Ashcraft, FDA, Woman, Supreme, Dietary supplement, Insurance, Pharmaceutical industry

Historically, bankruptcy cases filed to resolve litigation, including those related to asbestos, often take years, and almost never fully repay creditors, including personal injury victims.

Key Points: 
  • Historically, bankruptcy cases filed to resolve litigation, including those related to asbestos, often take years, and almost never fully repay creditors, including personal injury victims.
  • They also note that such an approach could immediately halt more than 34,000 claims by ovarian cancer victims and force all related litigation into bankruptcy court, rather than giving these victims their day in trial court before judges and juries.
  • "Johnson & Johnson has actively threatened attorneys for plaintiffs with this scheme to force out-of-court settlements at pennies on the dollar.
  • In May 2020, Johnson & Johnson announced the company would no longer make or market talc-based powders for the North American market.

Luminar Welcomes Four Auto-Tech Industry Leaders to Executive Team

Retrieved on: 
Thursday, August 19, 2021
Automotive Manufacturing, Hardware, Manufacturing, Technology, Software, Electrical engineering, Industry, Florida Institute of Technology, Architecture, OEM, University, EY, Program, Original equipment manufacturer, Growth, Economics, Ford Motor Company, Business, Aptiv, Wayne State University, PricewaterhouseCoopers, SAIC, Technology, S-1 Executive Committee, Nasdaq, Corporation, Car, J&J, Airbus, Johnson & Johnson, CIO, Electronics, University of Madras, Waymo, Business operations, Safety, Pony.ai, ZF Friedrichshafen, CEO, GE Healthcare, GCA, Nyāya Sūtras, Deutsche Bank, M&A, VP, Deloitte, Volvo, SUV, Business administration, Executive Committee, Williams College, Computer, Management

Were hyper focused on taking Luminar to the next level in this new phase of growth and execution.

Key Points: 
  • Were hyper focused on taking Luminar to the next level in this new phase of growth and execution.
  • Each of our new leaders are at the top of their respective fields in the industry, and will be relentlessly driving Luminar towards series production as the new automotive safety and autonomy standard, said Luminar Founder and CEO, Austin Russell.
  • Munir Hafez joins Luminar as Chief Information Officer (CIO), after serving as CIO at Aptiv for their autonomous mobility group.
  • Cheryl Zula joined Luminar to lead sourcing and supply chain after serving as a global supply chain and purchasing executive at Stellantis.

NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19

Retrieved on: 
Wednesday, August 18, 2021
Extracorporeal membrane oxygenation, VIP, National, Dark Enlightenment, Government, ASPE, Biomedical Advanced Research and Development Authority, Fast Track, Human services, Letter, Critical, Remdesivir, Review, Private Securities Litigation Reform Act, Food, Data monitoring committee, Health, JD, J&J, Lilly, Critical care, Biology, IIBR-100, Biotechnology, MPH, Development, NASDAQ, Safety, Goal, Patient, Novartis, Aviptadil, US Foods, Failure rate, National Security Advisor (United States), FDA, United States Army, Vasoactive intestinal peptide, COVID-19, Breakthrough therapy, Israel Institute for Biological Research, Pharmaceutical industry

The study's Data Safety Monitoring Board found no new safety concerns in the trial and recommended continued enrollment.

Key Points: 
  • The study's Data Safety Monitoring Board found no new safety concerns in the trial and recommended continued enrollment.
  • Study investigators are randomizing patients to receive one of four treatment regimens in addition to standard of care: both ZYESAMI and remdesivir, ZYESAMI and a placebo, remdesivir and placebo, or only placebo.
  • NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific and drug-development experience to bring improved health to patients.
  • This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S.

NRx Pharmaceuticals to Report Second Quarter 2021 Results August 16, 2021

Retrieved on: 
Wednesday, August 11, 2021
COVID, National, Patient, General officer, Goal, JD, Israel Institute for Biological Research, COVID-19, United States Army, FDA, J&J, Conference, MPH, Novartis, GLOBE, Nasdaq, Private Securities Litigation Reform Act, Health, Letter, Biology, Biotechnology, International, Dark Enlightenment, US Foods, Biomedical Advanced Research and Development Authority, Human services, Webcast, Government, Food, Breakthrough therapy, ASPE, Lilly, National Security Advisor (United States), Development, Pharmaceutical industry

RADNOR, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company, today announced that management will report second quarter 2021 financial results after the market close on August 16, 2021. The company will host a conference call and webcast on August 17, 2021, 8:30 AM Eastern Time to discuss its results and provide a clinical and corporate update. Management will host the call, followed by a question-and-answer period. Analysts and investors interested in submitting questions must do so in advance of the call and are encouraged to email questions to the Company’s investor relations representative at [email protected].

Key Points: 
  • --Company to Host Conference Call August 17, 2021 at 8:30AM ET--
    RADNOR, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company, today announced that management will report second quarter 2021 financial results after the market close on August 16, 2021.
  • A replay will be available from the NRx Pharmaceuticals website following the call at www.nrxpharma.com .
  • NRx Pharmaceuticals (www.nrxpharma.com) (NRx) draws upon more than 300 years of collective, scientific and drug-development experience to bring improved health to patients.
  • This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S.

Christopher DelOrefice to Join BD as Chief Financial Officer

Retrieved on: 
Wednesday, August 11, 2021
Certification, Education, Therapy, Health, Calendar, Safety, Medical device, Company, LinkedIn, Patient, Becton, Dickinson and Company headquarters, Efficiency, BD, Investor relations, J&J, TGS, Organization, Business administration, CFO, Commonwealth, Solution, NYSE, Technology, CEO, Ametek, Consumer, Twitter, Global, Villanova University, Commercial, IBM Global Services, BDX, Leadership, Disease, Becton, Johnson & Johnson, Management

FRANKLIN LAKES, N.J., Aug. 11, 2021 /PRNewswire/ --BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Christopher DelOrefice has been named executive vice president and chief financial officer (CFO), effective Sept. 6, 2021.

Key Points: 
  • FRANKLIN LAKES, N.J., Aug. 11, 2021 /PRNewswire/ --BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Christopher DelOrefice has been named executive vice president and chief financial officer (CFO), effective Sept. 6, 2021.
  • DelOrefice succeeds Christopher Reidy, 64, who announced his intent to retire from BD last week.
  • DelOrefice, 50, will join BD from Johnson & Johnson (J&J), where he is currently vice president of Investor Relations.
  • For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo .

In an up-to $200M Acquisition by Nanox, Zebra Medical Vision Brings Its AI to Reimagine Radiology Globally

Retrieved on: 
Tuesday, August 10, 2021
Technology, Mobile, Wireless, Medical Devices, Other Technology, Software, Other Health, Radiology, Health, Data Management, Aurum, Adoption, Achievement, CEO, USD, Patient, Diagnosis, Health, Sudarshan K. Aggarwal, ARC, Machine learning, Khosla Ventures, American College, Risk, Hospital, J&J, Technology, Solution, Fast Company, Internationalized domain name, Multimedia, Population, Acquisition, NASDAQ, Disease, CPT, FDA, Conditional sentence, ACR, AI, Medical device

As a result of the acquisition, the medical imaging pioneers will leverage Zebra-Meds industry-leading team, cutting-edge AI technology and cloud capabilities, and unprecedented regulatory framework to form the next-generation medtech juggernaut.

Key Points: 
  • As a result of the acquisition, the medical imaging pioneers will leverage Zebra-Meds industry-leading team, cutting-edge AI technology and cloud capabilities, and unprecedented regulatory framework to form the next-generation medtech juggernaut.
  • Zebra Medical Vision has always operated with the goal of expanding the use of AI in medical imaging to improve health outcomes for patients worldwide, says Zohar Elhanani, CEO of Zebra Medical Vision.
  • Screening populations to detect and treat chronic disease early on, while establishing new care pathways, has significantly improved treatment outcomes.
  • Zebra Medical Vision has raised $52 million in funding to date, and was named a Fast Company Top-5 AI and Machine Learning company.